Forbes April 9, 2021
Joshua Cohen

It’s been suggested in some circles that the newly confirmed Secretary of Health and Human Services, Xavier Becerra, poses a greater threat than his predecessor, Alex Azar, to the pharmaceutical industry. This, however, may not be the case, at least not in terms of prescription drug pricing per se. Instead, Becerra is likely to focus his attention more broadly on anti-competitive practices throughout the healthcare system, in all sectors, including prescription drugs.

Although Becerra has long been an advocate for Medicare for All, legislatively, at this point in time, such a radical overhaul of the healthcare system is a non-starter. Rather, Becerra could become an anti-trust enforcer, and perhaps be a signal caller for legislation to curb anti-competitive practices by...

Today's Sponsors

Institute for Healthcare Improvement
Crossover Health

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Govt Agencies, Health System / Hospital, HHS, Pharma, Pharma / Biotech, Provider
HHS Issues Threat Warning to US Healthcare Sector
HHS sets out plans to make medical device, diagnostics supply chains pandemic-proof
Corporate Integrity Agreements: A Year in Review
HHS distributing $560 Million to physicians affected by the pandemic
HHS expands U.S.-based pharmaceutical manufacturing to get drugs to hospitals faster